MELISSA RANZER: Open Payments
NPI 1912668120 · MOUNT LAUREL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,683 in 76 payments from 15 companies in 2025. Trend: 2023 $1,376 · 2024 $1,463 · 2025 $1,683
Food & beverage: $1,683
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $421 |
| GENZYME CORPORATION | 6 | $220 |
| Ardelyx, Inc. | 14 | $188 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $180 |
| Gilead Sciences, Inc. | 3 | $152 |
| Celltrion USA Inc. | 1 | $123 |
| Janssen Biotech, Inc. | 4 | $97 |
| Regeneron Healthcare Solutions, Inc. | 5 | $95 |
| Lilly USA, LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
Products named: DUPIXENT, RINVOQ, IBSRELA, XIFAXAN, ZYMFENTRA, TREMFYA, OMVOH, MAVYRET.
Industry payments across NJ — which companies pay providers there.
